Kim N. Chi

LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO).

B. Alekseev, K. Chi, N. Tran, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice

S. Hotte, U. Emmenegger, T. Niazi, 2024, Current oncology.

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

N. Agarwal, A. Barnicle, A. Thiery-Vuillemin, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

2023 Canadian Urological Association guideline: Genetic testing in prostate cancer.

K. Schrader, S. Selvarajah, T. Niazi, 2023, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy.

S. McCarthy, S. Mundle, A. Bhaumik, 2024, BJU international.

Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer.

P. De Porre, S. McCarthy, S. Mundle, 2023, European urology oncology.

Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN

N. Agarwal, B. Gartrell, C. Pieczonka, 2023, British journal of cancer.

Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial.

Oliver Sartor, Bernd J. Krause, R. Ghouse, 2024, Cancer.